Skip to main content

BeOne Medicines Ltd.

BEIGF
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001651308

In the last 90 days, BeOne Medicines Ltd. insiders filed 0 open-market purchases and 9 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Other share classesONC

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Nov 8, 2026, 10:55 PM ET

Revenue flow, FY2025

Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.

Income statement

Each column is one fiscal year, newest first.

Income statement of BeOne Medicines Ltd., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedFeb 26, 2026Feb 27, 2025Feb 26, 2024Feb 27, 2023Feb 25, 2022
Revenue$5.34B$3.81B$2.46B$1.42B$1.18B
Cost of revenue–––$286.5M$164.9M
Gross profit$4.67B$3.22B$2.08B––
Research and development$2.15B$1.95B$1.78B$1.64B$1.46B
Selling, general and administrative$2.08B$1.83B$1.50B$1.28B$990.1M
Operating income$447.1M-$568.2M-$1.21B-$1.79B-$1.44B
Interest expense$50.0M$46.9M$20.8M$21.7M$29.3M
Income tax$129.9M$111.8M$55.9M$42.8M-$25.2M
Net income$286.9M-$644.8M-$881.7M-$2.00B-$1.41B
EPS, basic$0.20$-0.47$-0.65$-1.49$-1.17
EPS, diluted$0.19$-0.47$-0.65$-1.49$-1.17
Weighted shares, basic1.42B1.37B1.36B1.34B1.21B
Weighted shares, diluted1.47B1.37B1.36B1.34B1.21B
Margins and growth
Gross margin87.5%84.4%84.5%––
Operating margin8.4%-14.9%-49.1%-126.4%-122.3%
Net margin5.4%-16.9%-35.9%-141.5%-120.2%
Revenue growth, year over year+40.2%+55.0%+73.7%+20.4%+280.8%

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of BeOne Medicines Ltd., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedFeb 26, 2026Feb 27, 2025Feb 26, 2024Feb 27, 2023Feb 25, 2022
Cash and equivalents$4.55B$2.63B$3.17B$3.87B$4.38B
Short-term investments––$2.60M$665.3M$2.24B
Accounts receivable$865.1M$676.3M$358.0M$173.2M$483.1M
Inventory$608.2M$495.0M$416.1M$282.3M$242.6M
Total current assets$6.23B$3.99B$4.20B$5.21B$7.61B
Property, plant and equipment$1.64B$1.58B$1.32B$845.9M$587.6M
Goodwill–––$109.0K$109.0K
Intangible assets$62.7M$51.1M$57.1M$40.6M$46.7M
Total assets$8.19B$5.92B$5.81B$6.38B$8.65B
Accounts payable$479.0M$405.0M$315.1M$294.8M$262.4M
Short-term debt$9.06M$851.5M$688.4M$329.0M$427.6M
Total current liabilities$1.83B$2.21B$1.81B$1.47B$1.60B
Long-term debt$961.9M$166.5M$197.6M$209.1M$202.1M
Total liabilities$3.83B$2.59B$2.27B$2.00B$2.40B
Shareholders' equity$4.36B$3.33B$3.54B$4.38B$6.24B

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of BeOne Medicines Ltd., annual
Line itemFY2025FY2024FY2023FY2022FY2021
Period endDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021
Filing10-K10-K10-K10-K10-K
ReportedFeb 26, 2026Feb 27, 2025Feb 26, 2024Feb 27, 2023Feb 25, 2022
Operating cash flow$1.13B-$140.6M-$1.16B-$1.50B-$1.30B
Capital expenditures$185.8M$492.7M$561.9M$325.4M$262.9M
Free cash flow$941.7M-$633.3M-$1.72B-$1.82B-$1.56B
Depreciation and amortization$141.7M$171.8M$87.7M$66.3M$46.5M
Stock-based compensation$510.9M$441.6M$367.6M$303.2M$240.7M
Investing cash flow-$276.2M-$548.4M$60.0M$1.08B$640.7M
Financing cash flow$1.06B$193.4M$416.5M-$19.0M$3.64B
Net change in cash$1.97B-$547.2M-$689.1M-$507.9M$2.99B
Ratio
Stock-based compensation, % of revenue9.6%11.6%15.0%21.4%20.5%

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for BeOne Medicines Ltd. by cover date
Cover dateShares outstandingChange in a yearFiling
Oct 30, 20261.48B+3.2%SEC
Jul 31, 20261.48B+3.3%SEC
Apr 30, 20261.45B+3.0%SEC
Feb 13, 20261.44B+4.0%SEC
Nov 1, 20251.44B+3.8%SEC
Aug 1, 20251.43B+3.7%SEC
May 2, 20251.40B+3.2%SEC
Feb 14, 20251.39B+2.0%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.